文献
J-GLOBAL ID:201702276106145367
整理番号:17A1707034
進行黒色腫のためのPembrolizumabとイピリムマブ:多施設,無作為化,非盲検第3相試験(KEYNOTE 006)の最終全生存率結果【Powered by NICT】
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
著者 (20件):
Schachter Jacob
(Division of Oncology, Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel)
,
Ribas Antoni
(Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA)
,
Long Georgina V
(Department of Medical Oncology and Translational Research, Melanoma Institute Australia, The University of Sydney, Mater Hospital and Royal North Shore Hospital, Sydney, Australia)
,
Arance Ana
(Department of Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain)
,
Grob Jean-Jacques
(Department of Dermatology and Skin Cancer, Aix Marseille University, Hopital de la Timone, Marseille, France)
,
Mortier Laurent
(Department of Dermatology, Universite Lille, INSERM U1189, CHU Lille, F-59000, France)
,
Daud Adil
(Department of Hematology/Oncology, University of California, San Francisco, San Francisco, CA, USA)
,
Carlino Matteo S
(Department of Medical Oncology, Westmead and Blacktown Hospitals, Melanoma Institute Australia, and The University of Sydney, Sydney, Australia)
,
McNeil Catriona
(Department of Medical Oncology, Chris O’Brien Lifehouse, Royal Prince Alfred Hospital, and Melanoma Institute Australia, Camperdown, Australia)
,
Lotem Michal
(Department of Melanoma and Cancer Immunotherapy, Sharett Institute of Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel)
,
Larkin James
(Department of Medical Oncology, Royal Marsden Hospital, London, UK)
,
Lorigan Paul
(Department of Medical Oncology University of Manchester and the Christie NHS Foundation Trust, Manchester, UK)
,
Neyns Bart
(Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium)
,
Blank Christian
(Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands)
,
Petrella Teresa M
(Department of Medicine, Division of Medical Oncology/Hematology, Sunnybrook Health Sciences Center, Toronto, ON, Canada)
,
Hamid Omid
(Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Los Angeles, CA, USA)
,
Zhou Honghong
(Department of BARDS, Merck & Co, Kenilworth, NJ, USA)
,
Ebbinghaus Scot
(Department of Clinical Oncology, Merck & Co, Kenilworth, NJ, USA)
,
Ibrahim Nageatte
(Department of Clinical Oncology, Merck & Co, Kenilworth, NJ, USA)
,
Robert Caroline
(Department of Oncology, Gustave Roussy and Paris-Sud University, Villejuif, France)
資料名:
Lancet
(Lancet)
巻:
390
号:
10105
ページ:
1853-1862
発行年:
2017年
JST資料番号:
B0673A
ISSN:
0140-6736
CODEN:
LANCA
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)